Show simple item record

dc.contributor.advisorAfrica, Charlene WJ
dc.contributor.authorJohn, Cathy Nisha
dc.date.accessioned2021-02-25T09:00:24Z
dc.date.available2021-02-25T09:00:24Z
dc.date.issued2019
dc.identifier.urihttp://hdl.handle.net/11394/7889
dc.descriptionPhilosophiae Doctor - PhDen_US
dc.description.abstractBackground: Oropharyngeal candidiasis, caused by the fungus Candida, is the most common opportunistic infection affecting the quality of life of immunocompromised patients. Fluconazole is widely used as the first line of treatment for fungal infections. However, the inappropriate and misguided use of the drug has led to the evolvement of fluconazole-resistant Candida organisms. This arising resistance resulted in the urgent need for the development of new antimicrobial drugs. The aim of the present study was to investigate the antifungal action of K21, a novel antimicrobial quarternary ammonium compound, on fluconazole-resistant Candida species.en_US
dc.language.isoenen_US
dc.publisherUniversity of Western Capeen_US
dc.subjectQuaternary ammonium compoundsen_US
dc.subjectK21 antimicrobial compounden_US
dc.subjectFluconazoleen_US
dc.subjectCandidaen_US
dc.subjectAntifungal susceptibilityen_US
dc.titleProtein expression and antifungal effect of fluconazole-resistant Candida species following effective in vitro treatment with K21, a novel antifungal agenten_US
dc.rights.holderUniversity of Western Capeen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record